Bellerophon Therapeutics, Inc. (BLPH)
OTCMKTS: BLPH · Delayed Price · USD
0.0510
0.00 (0.00%)
Jul 19, 2024, 4:00 PM EDT - Market open
Bellerophon Therapeutics Employees
Bellerophon Therapeutics had 18 employees as of December 31, 2022. The number of employees decreased by 2 or -10.00% compared to the previous year.
Employees
18
Change (1Y)
-2
Growth (1Y)
-10.00%
Revenue / Employee
$313,333
Profits / Employee
-$648,333
Market Cap
623.86K
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher | 122,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
| Danaher | 63,000 |
BLPH News
- 1 year ago - Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH) - Benzinga
- 1 year ago - Bellerphon Therapeutics stock plunges toward record selloff after lung disease treatment performs worse than placebo in late-stage trial - Market Watch
- 1 year ago - Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease - GlobeNewsWire
- 1 year ago - Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results - GlobeNewsWire
- 1 year ago - Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease - GlobeNewsWire
- 1 year ago - Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results - GlobeNewsWire
- 1 year ago - Bellerophon Therapeutics Announces $5 Million Registered Direct Offering - GlobeNewsWire
- 1 year ago - Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease - GlobeNewsWire